Da An Gene approves 2024 resolutions at shareholder meeting

Da An Gene (SZSE:002030) announced the resolutions passed at its 2024 annual shareholder meeting held on April 18, 2025. Shareholders approved the 2024 Board of Directors and Supervisory Board work reports with near-unanimous support, alongside the 2024 financial statements. The proposed 2024 profit distribution plan and the 2025 daily related transaction estimates were also ratified, although the latter saw abstentions from related parties to avoid conflicts of interest. Furthermore, shareholders approved the use of idle funds for cash management and the application to terminate the listing of a subsidiary, Zhuhai Yasha Biotechnology, on the National Equities Exchange and Quotations (NEEQ) system. The meeting was conducted through a combination of on-site and online voting, ensuring broad shareholder participation.